Avadel Pharmaceuticals plc (AVDL)
$21.67+0.05%Close
SELLBULL · day 71
Key stats
- Market cap
- $2.1B
- Beta
- 1.31
- P/E (TTM)
- 215.97
- 1W
- +0.28%
- 1M
- +0.42%
- vs SPY 1W
- +0.42%
- vs SPY 1M
- -2.09%
Industry peers
FMP comparable companies · ranked by market cap
- OGNBUYOrganon & Co.$3.6BBULLQ -2$13.75+0.00%
- GRDNSELLGuardian Pharmacy Services, Inc.$2.6BBEARQ 57$41.60-1.63%
- MDBUYPediatrix Medical Group, Inc.$2.2BBULLQ 15$26.24-1.15%
- ALVOBUYAlvotech$1.9BCRISISQ -4$5.67-2.18%
- ANIPSELLANI Pharmaceuticals, Inc.$1.6BRECOVERYQ 9$71.98-3.74%
- PAHCBUYPhibro Animal Health Corporation$1.5BRECOVERYQ 10$37.40-1.66%
- QDELBUYQuidelOrtho Corporation$846MRECOVERYQ 8$12.41+6.42%
- EVOSELLEvotec SE$558MCRISISQ 16$1.57-1.46%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on AVDL?
- LOPJLB’s latest quantitative signal on Avadel Pharmaceuticals plc (AVDL) is SELL in a BULL regime. Signals are updated daily.
- What market regime is AVDL in?
- Avadel Pharmaceuticals plc (AVDL) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Avadel Pharmaceuticals plc (AVDL) do?
- Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with…